UPDATE 1-Merck's bowel disease drug meets main goal in late-stage trial

Merck & Co., Inc.

Merck & Co., Inc.

MRK

0.00

Adds details on the drug and trial in paragraphs 2 to 5

June 22 (Reuters) - Merck MRK.N said on Monday its drug met the main goal in a late-stage trial testing it in patients with a type of inflammatory bowel disease.

After 12 weeks, the drug, tulisokibart, showed clinical remission in symptoms of ulcerative colitis.

Ulcerative colitis is a type of chronic bowel disease that causes long-lasting inflammation and ulcers in the innermost lining of the large intestine and rectum.

Merck said results from the trial will be presented with the those from an ongoing maintenance study at an upcoming scientific congress.

Tulisokibart is currently being tested as a treatment for seven diseases, including ulcerative colitis, Merck said.



This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.